ライフサイエンスコーパス: positron emission

1 tic plaques can be visualized by noninvasive positron emission and computed tomographic imaging with

2 Using combined positron emission and computed tomography in 35 asymptom

3 Visual assessment of amyloid positron emission tomographic (PET) images has been appr

4 y fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emission tomographic (PET) imaging are linked w

5 n 11-labeled Pittsburgh Compound B (11C-PiB) positron emission tomographic (PET) imaging.

6 (11)C-(R)-rolipram positron emission tomographic (PET) scans were performed

7 Using [11C]DPA-713 positron emission tomographic data from 12 active or for

8 Investigations in humans have used positron emission tomographic metabolic and myocardial b

9 ere unchanged, and a fluorodeoxyglucose F 18 positron emission tomographic scan was normal.

10 s underwent fludeoxyglucose F 18 ([18F]-FDG) positron emission tomographic scanning for assessment of

11 computed tomography, and fluorodeoxyglucose positron emission tomographic scans revealed strikingly

12 This cross-sectional case-control positron emission tomographic study was performed in the

13 mmunology, human translational research, and positron emission tomographic vascular imaging.

14 ed in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imagi

15 Eight patients with asthma completed positron emission tomographic/computed tomographic lung

16 d potentially have changed 332 of 1732 (19%) positron emission tomographies at low-risk physiological

17 s of 1344 pixel range of perfusion in paired positron emission tomographies.

18 n was assessed by MRI and fludeoxyglucose-18 positron emission tomography ((18)FDG-PET).

19 Combined oxygen 15-labeled positron emission tomography (15O PET) and brain tissue

20 ion delivered to the liver utilizing an oral positron emission tomography (18) F-isotopologue validat

21 using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]FDG PET), [(18)F]FD

22 Whole-body (18)F-fluodeoxyglucose positron emission tomography ([(18)F]FDG-PET) imaging ha

23 (18)F-Fluorodeoxyglucose-positron emission tomography (FDG-PET) has become a cent

24 l that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determ

25 t and high-resolution (18)fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to unders

26 ce imaging (MRI) and (18)F-fluordeoxyglucose positron emission tomography (FDG-PET).

27 pir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau a

28 We show that immuno-positron emission tomography (immuno-PET) can visualize

29 Positron emission tomography (PET) -computed tomography

30 Combined positron emission tomography (PET) and computed tomograp

31 single-photon emission tomography (SPECT) or positron emission tomography (PET) and coronary computed

32 hcare, Shanghai, China) followed by combined positron emission tomography (PET) and CT (hereafter, PE

33 (18)F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighte

34 y menstruating, asymptomatic women completed positron emission tomography (PET) and functional magnet

35 fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) and hyperpolarized ca

36 18 ((18)F) fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and magnetic resonanc

37 h-resolution neuroimaging data consisting of positron emission tomography (PET) and magnetic resonanc

38 Nevertheless, studies using positron emission tomography (PET) and radioligands for

39 vity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and survival in patie

40 22 healthy recreationally active males using positron emission tomography (PET) and the MOR-selective

41 is to synthesise current evidence on amyloid-positron emission tomography (PET) burden and presumed p

42 racy of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with diagnos

43 d mass spectrometric detection to quantify a positron emission tomography (PET) detection tracer for

44 fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) has added value over

45 Dynamic positron emission tomography (PET) images were acquired

46 BACKGROUND AND Amyloid-positron emission tomography (PET) imaging (API) detects

47 Positron emission tomography (PET) imaging agents that d

48 Positron Emission Tomography (PET) imaging allows the es

49 ing (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and internal

50 Amyloid positron emission tomography (PET) imaging is a valuable

51 exploited the potential targeting of TF for positron emission tomography (PET) imaging of pancreatic

52 Over the past years, positron emission tomography (PET) imaging studies have

53 Here we describe positron emission tomography (PET) imaging with (18)F-Ma

54 Positron emission tomography (PET) imaging with radiotra

55 ized male nonhuman primates (n = 3), we used positron emission tomography (PET) imaging with the radi

56 employed in the realm of nanoparticle-based positron emission tomography (PET) imaging, whereas its

57 g, or synthetic organic molecule for in vivo positron emission tomography (PET) imaging.

58 ased attenuation correction (ATAC) for brain positron emission tomography (PET) in an integrated time

59 Use of [(18)F]FDG-positron emission tomography (PET) in clinical breast ca

60 surgery on the human brain immune system by positron emission tomography (PET) in relation to blood

61 Positron emission tomography (PET) is a powerful analyti

62 Here, we show that positron emission tomography (PET) is advantageous for d

63 Positron emission tomography (PET) is an important drive

64 18-Fluorodeoxyglucose positron emission tomography (PET) is commonly utilized

65 tem (CNS) disorders, we sought to identify a positron emission tomography (PET) ligand to enable targ

66 ed that fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) may detect the inflam

67 tional magnetic resonance imaging (fMRI) and positron emission tomography (PET) multimodal imaging wi

68 DPGM) is developed for MR/photoacoustic (PA)/positron emission tomography (PET) multimodal imaging-gu

69 Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technolo

70 The method uses positron emission tomography (PET) of [(11)C]yohimbine b

71 Positron emission tomography (PET) offers superior contr

72 Here, we characterize a positron emission tomography (PET) probe for imaging DIP

73 by analyzing motor defects and binding of a positron emission tomography (PET) radioligand to the ve

74 ation is possible with the recent advance in positron emission tomography (PET) radioligands that bin

75 ch toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using th

76 Radiolabeling with long-lived positron emission tomography (PET) radionuclides, such a

77 (CCR2)-binding peptide adapted for use as a positron emission tomography (PET) radiotracer for nonin

78 While the benefits of MRI are many, positron emission tomography (PET) radiotracers are stil

79 A positron emission tomography (PET) scan confirmed the lu

80 Early response evaluation with positron emission tomography (PET) scan may improve sele

81 Ten subjects also completed a positron emission tomography (PET) scan to quantify DRN

82 nonsmokers participated in two [(11)C]ABP688 positron emission tomography (PET) scans on the same day

83 Previous positron emission tomography (PET) studies targeting the

84 ur objective was to determine the pattern of positron emission tomography (PET) tau tracer AV-1451 up

85 racer [(11)C]DAA1106 (a ligand for TSPO) and positron emission tomography (PET) to determine the effe

86 a radioligand that binds to the mGluR5, and positron emission tomography (PET) to quantify in vivo m

87 calisation and magnitude of the presumed tau Positron Emission Tomography (PET) tracer [(18)F]Flortau

88 Recent studies have shown that positron emission tomography (PET) tracer AV-1451 exhibi

89 individuals: (1) Tau, detected with a novel positron emission tomography (PET) tracer known as (18)F

90 Consequently, positron emission tomography (PET) tracers addressing tr

91 )-3 ([(11)C]-(R)-IPMICF16), a first-in-class positron emission tomography (PET) TrkB/C-targeting radi

92 They came to an academic research center for positron emission tomography (PET) using [(18)F]fallypri

93 duced D2R internalization can be imaged with positron emission tomography (PET) using D2R radiotracer

94 Positron emission tomography (PET) using radiolabeled li

95 ents of the New York metropolitan area using Positron Emission Tomography (PET) with [(11)C]racloprid

96 n of dopamine to value-based attention using positron emission tomography (PET) with [(11)C]racloprid

97 Purpose To demonstrate that positron emission tomography (PET) with fluorine 18 ((18

98 d tumor cytopenia on repeat (68)Ga-DOTA-TATE positron emission tomography (PET) within 6 months, sugg

99 d included magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon em

100 sease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their associatio

101 Radiocaine, an F-18 radiotracer for positron emission tomography (PET), is the first SCN5A i

102 nitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magneti

103 g a combination of functional MRI (fMRI) and positron emission tomography (PET), we investigated whet

104 ANCE STATEMENT: We present a high-resolution positron emission tomography (PET)- and magnetic resonan

105 In our phase 2 study of positron emission tomography (PET)-adapted salvage thera

106 stine, prednisone (R-CHOP14) induction and a positron emission tomography (PET)-driven ASCT or standa

107 yloid deposition, measured using florbetapir positron emission tomography (PET).

108 (sr39tk) reporter gene for cell detection by positron emission tomography (PET).

109 entual application in molecular imaging with positron emission tomography (PET).

110 , a dopamine D2/D3 receptor radiotracer, and positron emission tomography (PET).

111 ton emission computed tomography (SPECT) and positron emission tomography (PET).

112 lthy comparison subjects using [(11)C]IMA107 positron emission tomography (PET).

113 -L1 VHH) to track PD-L1 expression by immuno-positron emission tomography (PET).

114 tion and whole-body dosimetry assessments by positron emission tomography (PET).

115 A positron emission tomography (PET)/ computed tomography

116 Purpose [(18)F]Sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (

117 Purpose To assess the accuracy of staging positron emission tomography (PET)/computed tomography (

118 time using a combination of autoradiography, positron emission tomography (PET)/computed tomography (

119 eath hold (DIBH) in fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (

120 In this report, a case of fire in a positron emission tomography (PET)/magnetic resonance (M

121 Materials and Methods An integrated positron emission tomography (PET)/magnetic resonance (M

122 e of flourine 18 ((18)F) fluorocholine (FCH) positron emission tomography (PET)/magnetic resonance (M

123 Purpose To develop a positron emission tomography (PET)/magnetic resonance (M

124 correction (AC) (termed deep MRAC) in brain positron emission tomography (PET)/MR imaging.

125 arbon 11-labeled Pittsburgh Compound B (PiB) positron emission tomography after long-term prospective

126 3) or elevated (n = 202) brain amyloid using positron emission tomography amyloid imaging or a cerebr

127 ents received a second Pittsburgh compound B positron emission tomography analysis.

128 inical evaluation and imaging at enrollment (positron emission tomography and 2-dimensional echo).

129 ers, and 18 nonsmokers who were scanned with positron emission tomography and [(11)C]raclopride, afte

130 14 healthy individuals using [(11)C]-acetate positron emission tomography and cardiovascular magnetic

131 disease, thanks to advances in MRI, amyloid positron emission tomography and cerebrospinal fluid bio

132 nt for pathogenesis and treatment.IMPORTANCE Positron emission tomography and computed tomography (PE

133 luorodeoxyglucose [FDG] avidity) measured by positron emission tomography and computed tomography at

134 Positron emission tomography and computed tomography ima

135 essment in patients with lymphoma, including positron emission tomography and computed tomography sca

136 stic accuracy of Fluor-18-fluorodeoxyglucose positron emission tomography and computed tomography, la

137 d 77 years underwent 11C-(R)PK11195, 11C-PIB positron emission tomography and magnetic resonance imag

138 d the activity of the PSMA-PI3K axis through positron emission tomography and magnetic resonance imag

139 tients underwent (11)C-Pittsburgh compound B positron emission tomography and magnetic resonance imag

140 MENT We here show that combined simultaneous positron emission tomography and magnetic resonance imag

141 Hybrid positron emission tomography and magnetic resonance in t

142 20 min, and 50 min with (15)O-water by using positron emission tomography and MRI.

143 A meta-analysis of 142 positron emission tomography and single photon emission

144 ects and 23 healthy controls participated in positron emission tomography and structural magnetic res

145 agnetic resonance imaging, amyloid (11C-PiB) positron emission tomography and tau (18F-AV-1451) posit

146 he results of their florbetapir F-18 (Abeta) positron emission tomography and their Alzheimer disease

147 ndication of neuroinflammation in vivo using positron emission tomography and TSPO-specific radioliga

148 (18)F-fluorodeoxyglucose-positron emission tomography and ultrasmall superparamag

149 ter stress testing with myocardial perfusion positron emission tomography and with left ventricular e

150 Staging used positron emission tomography and/or computed tomography.

151 ned by fluorodeoxyglucose F 18 [FDG]-labeled positron emission tomography and/or hippocampal volume [

152 beta-cells in pigs and nonhuman primates by positron emission tomography as well as in immunodeficie

153 amyloid-beta plaques measured as florbetapir positron emission tomography binding antecedent to 18F-A

154 dementia) and 12 healthy controls underwent positron emission tomography brain imaging with [(18)F]A

155 tomography, magnetic resonance imaging, and positron emission tomography can be used to assess pulmo

156 Positron emission tomography can be useful to identify a

157 rticipants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18-FDG

158 cted by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET/CT

159 Systemic venous sampling and positron emission tomography confirm uptake of glucose a

160 s an insufficient explanation of 18F-AV-1451 positron emission tomography data in vivo, at least in t

161 Fluorodopa positron emission tomography demonstrated significant in

162 and insulin sensitivity were measured using positron emission tomography during an isoglycemic clamp

163 ose concentrations) with 1-[(11)C]-d-glucose positron emission tomography during hyperinsulinemic glu

164 nts underwent magnetic resonance imaging and positron emission tomography for amyloid-beta ((11) C-Pi

165 healthy control subjects had 11C-(R)-PK11195 positron emission tomography for comparison.

166 New radioligands for positron emission tomography have generated considerable

167 Positron emission tomography image analysis was complete

168 aphy with iron oxide particles, and targeted positron emission tomography imaging are currently under

169 New recommendations for positron emission tomography imaging for the evaluation

170 nflammation, were measured with [(11)C]PBR28 positron emission tomography imaging in 15 healthy contr

171 Positron emission tomography imaging of mice bearing PC3

172 Positron emission tomography imaging reveals neuroinflam

173 We assessed the radiotracer 18F-AV-1451 with positron emission tomography imaging to compare the dist

174 had available plasma total tau levels, Abeta positron emission tomography imaging, and a complete neu

175 l and structural magnetic resonance imaging, positron emission tomography imaging, and behavioral dat

176 structural MRI, [(18)F]flutemetamol amyloid positron emission tomography imaging, apolipoprotein E g

177 d quantitative techniques, including in vivo positron emission tomography imaging, gamma counting, an

178 sessments, seizures, corticosteroid use, and positron emission tomography imaging.

179 onic uptake of [(18)F]-fluorodeoxyglucose by positron emission tomography in Hdc(-/-) mice.

180 etic resonance imaging and spectroscopy, and positron emission tomography in these areas and discusse

181 We suggest that 18F-AV-1451 positron emission tomography is a useful biomarker to as

182 Although, currently positron emission tomography is the most commonly used t

183 Here we compared binding of tau positron emission tomography ligands, PBB3 and AV-1451,

184 ing fundamentals necessary to understand how positron emission tomography makes robust, quantitative

185 e in PCC fludeoxyglucose F 18 ([(18) F] FDG) positron emission tomography measured in Alzheimer's Dis

186 pleasant, and neutral images), and underwent positron emission tomography measurements of dopamine D2

187 latform for magnetic resonance/photoacoustic/positron emission tomography multimodal imaging and ligh

188 t state-of-the-art hardware and software for positron emission tomography myocardial perfusion imagin

189 lume of denervated myocardium (defect of the positron emission tomography norepinephrine analog (11)C

190 [(11)C]5-hydroxy-tryptophan ([(11)C]5-HTP) positron emission tomography of the pancreas has been sh

191 For amyloid positron emission tomography positive (Abeta+) subjects,

192 Here, we report the development of a positron emission tomography probe for live bacterial in

193 D2/3 agonist positron emission tomography radiotracer [(11)C]N-propyl

194 id (defined by cerebrospinal fluid assays or positron emission tomography regional summaries) can be

195 ated variability; and (iii) this 18F-AV-1451 positron emission tomography retention pattern significa

196 We found that: (i) 18F-AV-1451 positron emission tomography retention was differentiall

197 ed with age, and cross-sectional florbetapir positron emission tomography retention, but not with yea

198 t increased annualized change in florbetapir positron emission tomography retention.

199 11C-(R)-PK11195 positron emission tomography reveals increased inflammat

200 Investigations at progression included positron emission tomography scan and biopsy.

201 dard for reporting the results of an amyloid positron emission tomography scan is to assign a dichoto

202 tently associated with an Abeta+ florbetapir positron emission tomography scan, not all Abeta+ subjec

203 = 306) and (18) fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid

204 Positron emission tomography scanning with the transloca

205 F]fluoro-levo-dihydroxyphenylalanine dynamic positron emission tomography scans and striatal regions

206 resonance imaging and Pittsburgh compound B-positron emission tomography scans enrolled in the Mayo

207 3)I-MIBG scans, or [(18)F]fluorodeoxyglucose-positron emission tomography scans for MIBG-nonavid dise

208 eferred for rest/stress myocardial perfusion positron emission tomography scans from January 2006 to

209 ional resting-state (18)F-fluorodeoxyglucose positron emission tomography scans from VPA-exposed and

210 ne (MIBG) scans or [(18)F]fluorodeoxyglucose-positron emission tomography scans if the tumor is MIBG

211 atients were evaluated by fluorodeoxyglucose-positron emission tomography scans performed at baseline

212 DS AND In 127 volunteers, serial rest-stress positron emission tomography scans using rubidium-82 wit

213 D and 12 healthy controls (HC) completed two positron emission tomography scans with [(11)C]-(+)-PHNO

214 tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to what extent t

215 betapir retention, antecedent to 18F-AV-1451 positron emission tomography scans, in the parieto-tempo

216 [(18)F]Fludeoxyglucose positron emission tomography showed increased myocardial

217 on between 18 kDa translocator protein brain positron emission tomography signal, which arises largel

218 years), response (PR v CR) after R-CHOP, and positron emission tomography status at assignment (negat

219 usion, this is one of the first longitudinal positron emission tomography studies evaluating longitud

220 Positron emission tomography studies report either no di

221 e disorder (MDD), highlighting insights from positron emission tomography studies.

222 study and invited these individuals back for positron emission tomography study with [(18)F]-fluorode

223 imaging via photoacoustic, fluorescence, and positron emission tomography techniques.

224 We used [(11)C](R)-PK11195 positron emission tomography to compare TSPO availabilit

225 ulti-session [(15)O]-water and [(18)F]-FDOPA positron emission tomography to determine striatal blood

226 fluorodihydroxyphenyl-l-alanine ([18F]-DOPA) positron emission tomography to examine dopamine synthes

227 Here we used positron emission tomography to investigate whether feed

228 hy age-matched control individuals underwent positron emission tomography to measure cerebral metabol

229 Here, we used [(11)C]NOP-1A and positron emission tomography to measure the in vivo bind

230 We used in vivo positron emission tomography to test whether feeding tri

231 labeled with fluorine-18 ((18)F) are used in positron emission tomography to visualize, characterize

232 n tau tangle accumulation (measured with the positron emission tomography tracer 18F-AV-1451) associa

233 The advent of tau-targeted positron emission tomography tracers such as flortaucipi

234 evelopment of tools such as radioligands and positron emission tomography tracers that are not curren

235 Using tau-specific and Abeta-specific positron emission tomography tracers, we show that in vi

236 brain amyloid burden, as detected by amyloid positron emission tomography using 11C-Pittsburgh B comp

237 ith [(11)C]carfentanil and [(18)F]fluorodopa positron emission tomography using a high-resolution sca

238 x-matched control subjects had (18)F-AV-1451 positron emission tomography using a Siemens high-resolu

239 We acquired positron emission tomography using F18 flortaucipir (tau

240 1C-Pittsburgh compound B and 11C-(R)-PK11195 positron emission tomography was used to determine the a

241 [(18)F]CPFPX positron emission tomography was used to quantify A1AR a

242 Positron emission tomography was used to visualize neuro

243 on-human primates and in human studies using positron emission tomography were not consistent.

244 dy, flortaucipir tau and florbetapir amyloid positron emission tomography were obtained for 217 subje

245 Positron emission tomography with 18F-florbetapir and fl

246 f functional SGLT2 proteins in rodents using positron emission tomography with 4-[(18)F]fluoro-dapagl

247 iatal D2R binding potential (D2R BPND) using positron emission tomography with a D2R-selective radiol

248 (68)Gallium-DOTATATE positron emission tomography with computed tomography ((

249 t-Enhanced MRI (DCE-MRI) and Fludeoxyglucose Positron Emission Tomography(FDG-PET).

250 amyloid burden (measured by florbetapir F-18 positron emission tomography) and cognitive performance

251 ng cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer d

252 etic resonance imaging, nuclear imaging, and positron emission tomography) performed on an outpatient

253 onal neuroimaging ([(18)F]fluorodeoxyglucose positron emission tomography) with a fear-regulating ext

254 trial (Prediction of Arrhythmic Events with Positron Emission Tomography).

255 on emission tomography and tau (18F-AV-1451) positron emission tomography, and episodic and semantic

256 ical assessment, brain 18-fluorodeoxyglucose positron emission tomography, electroneurography, and EL

257 ontribute to disease profiles of 18F-AV-1451 positron emission tomography, especially in primary tauo

258 erebral Abeta on Pittsburgh Compound B (PiB) positron emission tomography, gait speed over 4.57 m (15

259 Using positron emission tomography, magnetic resonance spectro

260 We used [(18)F]AV-1451 and [(11)C]PiB positron emission tomography, structural MRI, and neurop

261 nonoffenders were included and examined with positron emission tomography, using the radioligand [(11

262 glucose uptake, assessed through noninvasive positron emission tomography, was an effective predictiv

263 perfusion and coronary flow reserve (CFR) by positron emission tomography, where submaximal stress pr

264 Finally, the authors review positron emission tomography-based imaging techniques to

265 Positron emission tomography-based regional measures of

266 Purpose Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT

267 ained from baseline (18)F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT

268 l present the analyses of centrally reviewed positron emission tomography-computed tomography (PET-CT

269 TV0 was measured by (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography in 108

270 cation, adenocarcinoma histology, and higher positron emission tomography-computed tomography N stage

271 r extracranial metastatic lesions on choline positron emission tomography-computed tomography, and se

272 Vascular inflammation was assessed with positron emission tomography-computed tomography.

273 the clinical use of RHL30 in the context of positron emission tomography-guided response assessment

274 n were measured using 18F-fluorodeoxyglucose positron emission tomography.

275 scular magnetic resonance, and (11)C-acetate positron emission tomography.

276 e to that achieved by expert assessment with positron emission tomography.

277 ostic index, and CFR was quantified by using positron emission tomography.

278 [(18)F]fluorodeoxyglucose ([(18)F]FDG) with positron emission tomography.

279 in the murine brain for up to one week using positron emission tomography.

280 preparation of potential tracers for use in positron emission tomography.

281 new radiotracers for molecular imaging with positron emission tomography.

282 stenosis underwent (18)F-fluorodeoxyglucose-positron emission tomography/computed tomographic imagin

283 med to determine whether 18F-fludeoxyglucose-positron emission tomography/computed tomography (FDG-PE

284 ng of surveillance [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PE

285 (18)F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT

286 ings from dual-energy spectral CT(DEsCT) and positron emission tomography/computed tomography (PET/CT

287 Previously, we demonstrated that positron emission tomography/computed tomography (PET/CT

288 ascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo

289 ned in a single hybrid imaging session using positron emission tomography/computed tomography or sing

290 rom 31 patients and results of early interim positron emission tomography/computed tomography scans i

291 ascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography, with g

292 -to-background ratio by 18fluorodeoxyglucose positron emission tomography/computed tomography.

293 ar inflammation led to the increasing use of positron emission tomography/computed tomography.

294 together to enable simultaneous tetramodal (positron emission tomography/fluorescence/Cerenkov lumin

295 Positron emission tomography/magnetic resonance imaging

296 New radiolabeled probes for positron-emission tomography (PET) are providing an ever

297 information that could be available from tau positron-emission tomography scans and its use to determ

298 metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.

299 netic melanin nanoparticles is developed for positron-emission tomography/magnetic resonance/photoaco

300 ecombinant cellular systems, and critically, positron-emission-tomography (PET) studies with a specif